Pui S. Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pui S. Tan has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Alberto J. Montero
Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
1 shared publicationBenjamin Haaland
Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore. ; Department of Statistics and Applied Probability, National University of Singapore, Singapore
1 shared publicationChristos E. Kyriakopoulos
Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
1 shared publicationGilberto Lopes
Hospital do Coração Cancer Center (HCor Onco), Brazil. ; Centro Paulista de Oncologia, Brazil. ; Oncoclinicas do Brasil, Brazil. ; Johns Hopkins University, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 8, 29-36
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
Introduction: This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel. Methods: A search for published phase 3 trials was performed with PubMed. Indirect comparisons of enzalutamide (AFFIRM) to abiraterone acetate (COU-AA-301) on outcomes overall survival (OS), time to prostate-specific-antigen (PSA) progression, radiographic progression-free survival (PFS), and PSA response were constructed in the context of log-linear regression models. Results: There was no statistically significant difference in OS (hazard ratio (HR) 0.85, 95% CI 0.68–1.07). However, there was some evidence that enzalutamide may outperform abiraterone acetate with respect to secondary outcomes: time to PSA progression (HR 0.40, 95% CI 0.30–0.53), radiographic PFS (HR 0.61, 95% CI 0.50–0.74), and PSA response rates (RRs) (OR 10.69, 95% CI 3.92–29.20). Conclusion: While there was no statistically significant difference in OS, enzalutamide may be advantageous for secondary endpoints. Findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials.
- 1 January 2014
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 8, 29-36
Open AccessHormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
Introduction: This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel. Methods: A search for published phase 3 trials was performed with PubMed. Indirect comparisons of enzalutamide (AFFIRM) to abiraterone acetate (COU-AA-301) on outcomes overall survival (OS), time to prostate-specific-antigen (PSA) progression, radiographic progression-free survival (PFS), and PSA response were constructed in the context of log-linear regression models. Results: There was no statistically significant difference in OS (hazard ratio (HR) 0.85, 95% CI 0.68–1.07). However, there was some evidence that enzalutamide may outperform abiraterone acetate with respect to secondary outcomes: time to PSA progression (HR 0.40, 95% CI 0.30–0.53), radiographic PFS (HR 0.61, 95% CI 0.50–0.74), and PSA response rates (RRs) (OR 10.69, 95% CI 3.92–29.20). Conclusion: While there was no statistically significant difference in OS, enzalutamide may be advantageous for secondary endpoints. Findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials.